Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -69.9%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12M | $6M | $1M | $2M | $5M | $13M | $12M | $4M | $2M | $13M | $5M |
| Enterprise Value | $-9413750 | $-14747782 | $-3964561 | $-6871485 | $-6541931 | $-10944128 | $-1274655 | $-2086916 | $-12558822 | $9M | $-8108791 |
| P/E Ratio → | -0.69 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | 206.15 | 16.81 | 836.37 | 252.48 |
| P/B Ratio | 0.30 | 0.31 | 0.30 | 0.20 | 0.47 | 0.58 | 0.95 | 0.75 | 0.17 | 6.84 | 0.44 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | -99.38 | -91.01 | 597.63 | -426.78 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 100.0% | -3034.8% | -35700.0% | -28400.0% |
| Operating Margin | — | — | — | — | — | — | — | -42795.2% | -5336.2% | -93746.7% | -47447.4% |
| Net Profit Margin | — | — | — | — | — | — | — | -42419.0% | -5333.3% | -83013.3% | -47336.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -69.9% | -69.9% | -114.8% | -116.6% | -70.1% | -76.0% | -93.7% | -92.2% | -95.5% | -196.3% | -91.1% |
| ROA | -63.9% | -63.9% | -94.7% | -97.6% | -60.4% | -65.0% | -74.0% | -76.3% | -75.8% | -142.3% | -73.3% |
| ROIC | — | — | — | — | — | — | — | — | — | — | -785.3% |
| ROCE | -71.5% | -71.5% | -118.6% | -116.4% | -69.5% | -75.8% | -89.3% | -91.1% | -95.6% | -221.7% | -91.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.02 | 0.01 | 0.05 | 0.09 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.04 | -1.14 | -1.09 | -1.07 | -1.08 | -1.04 | -1.12 | -1.10 | -1.95 | -1.19 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -14073.00 | — |
Net cash position: cash ($21M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 49.37 | 49.37 | 5.65 | 5.71 | 6.42 | 8.06 | 6.91 | 3.88 | 8.69 | 1.69 | 5.16 |
| Quick Ratio | 49.37 | 49.37 | 5.65 | 5.71 | 6.42 | 8.06 | 6.91 | 3.88 | 8.69 | 1.69 | 5.16 |
| Cash Ratio | 48.35 | 48.35 | 5.30 | 5.20 | 6.08 | 7.84 | 6.49 | 3.69 | 8.53 | 1.58 | 5.08 |
| Asset Turnover | — | — | — | — | — | — | — | 0.00 | 0.01 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.7% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.7% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $787466 | $231508 | $126159 | $118684 | $42432 | $4262 | $1184 | $380 | $113 |
Clinical Trial Funding Exhaustion
Based on current financial data, PHIO trades at a price-to-book ratio of 0.29, which suggests that the market is heavily discounting the company's intellectual property and future clinical potential relative to its historical valuation and the broader biotechnology sector's typical pricing for early-stage research entities.
The low P/B multiple indicates that investors are assigning minimal value to the INTASYL platform, likely reflecting skepticism regarding its competitive positioning against established gene-editing technologies. This valuation level suggests that the market is pricing the equity closer to a liquidation scenario rather than a going-concern growth model.
As reported in recent financial statements, the company's current ratio has fluctuated significantly, reaching 66.93 in 2026Q1, yet this metric is misleading as it reflects a lack of current liabilities rather than an abundance of operational liquidity to fund long-term clinical development programs.
While the high current ratio appears superficially strong, it masks the reality that the firm lacks the recurring revenue necessary to sustain its high R&D burn rate. Investors should monitor the rapid depletion of cash reserves, which may necessitate dilutive financing well before the company reaches a meaningful clinical inflection point.
According to the provided financial data, the company's cash conversion cycle is characterized by extreme volatility, with accounts payable days reaching 31,275 in 2026Q1, which suggests that the firm is managing its limited cash by aggressively delaying vendor payments to preserve its dwindling liquidity position.
This extreme DPO figure is not indicative of operational efficiency but rather a defensive measure to extend the company's runway. Such reliance on vendor credit may eventually strain relationships with critical clinical research organizations, potentially jeopardizing the timeline for ongoing trials.
The current ratio is the most commonly misapplied metric for PHIO, as it obscures the company's fundamental inability to generate internal cash flow, thereby creating a false sense of security regarding the firm's actual financial health and its ongoing dependence on external capital markets.
For a pre-revenue biotech, analysts should prioritize 'months of cash runway' over standard liquidity ratios like the current or quick ratio. Relying on traditional balance sheet liquidity metrics fails to account for the high, non-discretionary nature of clinical trial expenditures that will inevitably consume the current cash balance.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PHIO stock.
Phio Pharmaceuticals Corp.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
Phio Pharmaceuticals Corp.'s return on equity (ROE) is -69.9%. The historical average is -141.9%.
Based on historical data, Phio Pharmaceuticals Corp. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.